Literature DB >> 18034955

Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain.

Y Shishido1, S Mitarai, K Otomo, M Seki, A Sato, I Yano, A Koyama, T Hattori.   

Abstract

SETTING: The Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine is the only vaccine against tuberculosis (TB), owing to its valuable protective effects and low virulence. However, it can occasionally cause systemic infection in immunocompromised hosts. Isoniazid (INH), rifampicin (RMP), streptomycin (SM) and ethambutol (EMB) are known to be effective anti-tuberculosis drugs and are used for the treatment of BCG infections. Unfortunately, there are few studies of the susceptibility of BCG vaccine strains to these drugs.
OBJECTIVE: To measure the minimum inhibitory concentrations (MICs) of BCG Tokyo vaccine products for anti-tuberculosis drugs and assess vaccine safety in terms of drug susceptibility.
DESIGN: We measured the MIC for one seed and five product lots of BCG Tokyo strain for INH, RMP, SM and EMB using Middlebrook 7H11 agar plates.
RESULTS: The MIC results for INH were 0.06 and 0.125 mg/ml for the product and seed lots, respectively. The MIC results for RMP, SM and EMB were 0.25-0.5, 0.25 and 2-4 microg/ml, respectively.
CONCLUSION: Our results indicate that the BCG Tokyo strain was susceptible to the major anti-tuberculosis drugs and treatable even in cases of severe adverse events, including systemic infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034955

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  4 in total

1.  Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.

Authors:  Nicole Ritz; Marc Tebruegge; Tom G Connell; Aina Sievers; Roy Robins-Browne; Nigel Curtis
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

2.  Ethambutol Is Cleared by a Contemporary High-Flux Hemodialyzer, and Drug Monitoring Ensures Safety and Therapeutic Effect.

Authors:  Rusheng Chew; Sarah Jongbloed; Dev Jegatheesan; Helen Healy; Kim Ta; Jacobus Ungerer; Brett McWhinney; Peter Donovan; Marion L Woods
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  Myobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinoma.

Authors:  Lucy Ping Aitchison; Viran Jayanetti; Steven T Lindstrom; Ronald Sekel
Journal:  Australas Med J       Date:  2015-10-31

4.  Inhalable Spray-Dried Chondroitin Sulphate Microparticles: Effect of Different Solvents on Particle Properties and Drug Activity.

Authors:  Susana Rodrigues; Ana M Rosa da Costa; Noelia Flórez-Fernández; María Dolores Torres; Maria Leonor Faleiro; Francesca Buttini; Ana Grenha
Journal:  Polymers (Basel)       Date:  2020-02-12       Impact factor: 4.329

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.